Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Cardinal Health 414 LLC is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. This workload is distributed across 3 distinct examiners, which indicates a moderate level of variety in the examination perspectives the company must address. The presence of 4 pending actions suggests an active phase of prosecution where multiple applications are simultaneously undergoing review. This volume requires a coordinated strategy to maintain consistency across different filings in the same sector.
The company's pending matters are organized within 2 distinct art units, concentrating the technical review into a limited number of specialized groups. SAMALA, JAGADISHWAR RAO is the busiest examiner for this portfolio, currently overseeing 2 pending office actions. Because this examiner handles 2 of the pending matters, they are responsible for a significant portion of the company's immediate patent office interactions. This concentration with a single examiner requires a consistent strategic approach to overcome the specific rejections or requirements issued in those two cases while managing the remaining actions with other officials.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAMALA, JAGADISHWAR RAO | 2 | 68.0% | +55.6% |
| LAU, JONATHAN S | 1 | 63.7% | -17.3% |
| VU, JAKE MINH | 1 | 41.1% | +27.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18351905 | MANNOSYLATED AMINE DEXTRAN DRUG DELIVERY VEHICLES WITH DEGRADABLE DISULFIDE/CARBONATE LINKERS TARGETING PAYLOADS TO CD206 EXPRESSING CELLS | LAU, JONATHAN S | 83d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17039409 | COMPOSITIONS AND RELATED METHODS FOR BLOCKING OFF-TARGET LOCALIZATION OF MANNOSYLATED DEXTRANS AND OTHER CD206 LIGANDS | SAMALA, JAGADISHWAR RAO | 80d overdue |
| 18189658 | Competitive Self-Blocking with Unlabeled Manocept Imaging Agents | VU, JAKE MINH | 12d |
| 17131087 | COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME | SAMALA, JAGADISHWAR RAO | — |
| Art Unit | Apps |
|---|---|
| 1618 | 3 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18351905 | MANNOSYLATED AMINE DEXTRAN DRUG DELIVERY VEHICLES WITH DEGRADABLE DISULFIDE/CARBONATE LINKERS TARGETING PAYLOADS TO CD206 EXPRESSING CELLS | LAU, JONATHAN S | 1693 | §102§103 | Non-Final OA | 83d | Pending | Jul 13, 2023 |
| 18189658 | Competitive Self-Blocking with Unlabeled Manocept Imaging Agents | VU, JAKE MINH | 1618 | §103 | Final Rejection | 12d | Pending | Mar 24, 2023 |
| 17131087 | COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME | SAMALA, JAGADISHWAR RAO | 1618 | §103 | Final Rejection | — | Pending | Dec 22, 2020 |
| 17039409 | COMPOSITIONS AND RELATED METHODS FOR BLOCKING OFF-TARGET LOCALIZATION OF MANNOSYLATED DEXTRANS AND OTHER CD206 LIGANDS | SAMALA, JAGADISHWAR RAO | 1618 | §103DP | Final Rejection | 80d overdue | Pending | Sep 30, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial